Free Trial

Kronos Bio Q1 2024 Earnings Report

Kronos Bio logo
$0.81 -0.02 (-2.06%)
As of 04/1/2025 04:00 PM Eastern

Kronos Bio EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Kronos Bio Revenue Results

Actual Revenue
$2.52 million
Expected Revenue
$1.50 million
Beat/Miss
Beat by +$1.02 million
YoY Revenue Growth
N/A

Kronos Bio Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Remove Ads

Kronos Bio Earnings Headlines

Kronos Bio Reports 2024 Financial Results
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
Kronos Bio reports Q4 EPS (43c) vs. (43c ) last year
Kronos Bio Insider Ups Holding By 36% During Year
See More Kronos Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kronos Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kronos Bio and other key companies, straight to your email.

About Kronos Bio

Kronos Bio (NASDAQ:KRON), a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

View Kronos Bio Profile

More Earnings Resources from MarketBeat